Last modification 54 there is
Electromagnetic Waves act on Nanorobots!
Electromagnetic Waves act on Nanorobots!Profession Gendarme - Apr 27, 2024
Electromagnetic Waves act on Vaxx Nanorobots to modify our Behavior and create Illnesses programmed by the Waves!
Mike Adams, researcher and activist, with Dr. Alphonzo Monzo, American naturopathic doctor specializing in biophysics and nanotechnology as a weapon, and its interaction with biology: By nanotechnology, we mean small machines generated naturally or in the presence of an electromagnetic field.
They self-assemble and can replicate inside the body.
This is a weapon.
The danger is that we don't know it.
The information is coming out, so there is hope.
Nanotechnology creates disease and changes behavior.
It interacts with electromagnetic waves!
Source: Changera4
Last modification 54 there is
CERN accelerator will be put into operation during the solar eclipse
CERN accelerator will be put into operation during the solar eclipseDigital Dawn - Apr 02, 2024
After a two-year hiatus, the European Organization for Nuclear Research's (CERN) particle accelerator will be used to search for particles hidden during the solar eclipse on April 8.
The machine, the Large Hadron Collider (LHC), blasts protons against each other to crack them open and study the subatomic particles they contain.
During next month's eclipse, the team of scientists will attempt to prove the existence of dark matter, which is estimated to make up about 28 percent of the universe, although it has never been known. view.
While the LHC typically runs for a month each year, it has been two years since it was brought back into operation after being shut down during the 2022 European energy crisis.
Last week, scientists revealed that a "ghost" structure had been discovered inside the particle collider.
Popular X account "Concerned Citizen" commented on CERN's solar eclipse tests and also noted that NASA will launch rockets named after an Egyptian serpentine deity during the event.
NASA's mission, known as Atmospheric Perturbations Around the Path of the Eclipse (APEP), was named in honor of the "serpent deity of ancient Egyptian mythology," who was a "nemesis of the divinity of the Sun, Ra”.
“It is said that Apep pursued Ra and, from time to time, almost consumed him, causing an eclipse,” reads the NASA website.
According to Ancient Egypt Online, “Apep was the ancient Egyptian spirit of evil, darkness and destruction. As the archenemy of the sun god Ra, he was a malevolent force that could never be entirely defeated. Every night, as the sun passed through the underworld (or sky), its roar filled the air and it launched its attack.”
The NASA project aims to study how the solar eclipse, by causing a sudden decrease in sunlight, affects Earth's upper atmosphere.
Last modification 54 there is
Predicative AI to detect volunteers for COVID-19 vaccination
Predicative AI to detect volunteers for COVID-19 vaccinationGuy Boulianne - March 26, 2024
A new artificial intelligence system is able to predict whether or not a person is ready to get vaccinated against COVID-19.
A powerful new artificial intelligence tool can predict whether a person is ready to get vaccinated against COVID-19. The system integrates the mathematics of human judgment with machine learning to predict vaccine hesitancy. The predictive system uses a small data set from demographics and personal judgments such as risk or loss aversion.
The findings frame a new technology that could have broad applications for predicting mental health and leading to more effective public health campaigns.
A team led by researchers from the University of Cincinnati and Northwestern University created a predictive model using an integrated system of mathematical equations describing legal patterns of reward and aversion judgment using machine learning.
“We used a small number of variables and minimal computational resources to make predictions,” said lead author Nicole Vike, a senior research associate in UC's College of Engineering and Applied Sciences.
“COVID-19 is unlikely to be the last pandemic we see for decades to come. Having a new form of artificial intelligence for public health prediction is a valuable tool that could help prepare hospitals to predict vaccination rates and subsequent infection rates. »
The study was published in the Journal of Medical Internet Research Public Health and Surveillance.
Researchers surveyed 3 adults across the United States in 476 during the COVID-2021 pandemic. At the time of the survey, the first vaccines had been available for more than a year.
Respondents provided information such as their location, income, highest level of education completed, ethnicity and internet access. The demographics of those surveyed mirrored those of the United States, according to figures from the U.S. Census Bureau. Participants were asked if they had received any of the available COVID-19 vaccines. About 73% of those surveyed said they had been vaccinated, slightly more than the 70% of the national population who were vaccinated in 2021.
Additionally, they were asked if they consistently followed four recommendations intended to prevent the spread of the virus: wearing a mask, maintaining social distancing, washing hands and not gathering in large groups.
Participants were asked to rate how much they liked or disliked a set of 48 randomly sequenced images on a seven-point scale from 3 to -3. The images were from the International Affective Picture Set, a large set of emotionally evocative color photographs, divided into six categories: sports, disasters, cute animals, aggressive animals, nature and food.
Vike said the goal of this exercise is to quantify the mathematical characteristics of people's judgments when they observe mildly emotional stimuli. Measures for this task include concepts familiar to behavioral economists—or even gamblers—such as risk aversion (the extent to which someone is willing to accept a potential loss for a potential reward) and risk aversion. loss. This is the desire to avoid risks, for example by taking out insurance.
“It can work very simply. It does not require super computing, is inexpensive, and can be applied to anyone with a smartphone. We call it Computational Cognitive AI. It is likely that you will see further requests for judgment changes in the very near future. »
Last modification 54 there is
A stunning act of scientific censorship
A stunning act of scientific censorshipThe Defender - March 05, 2024
Journal retracts peer-reviewed study criticizing Covid-19 vaccine.
On Monday, the journal Cureus retracted the first peer-reviewed paper that presented an in-depth analysis of Covid-19 mRNA vaccine trial data and post-injection injury. The authors of the article also called for a global moratorium on vaccines.
On Monday, the journal Cureus retracted the first peer-reviewed paper that presented an in-depth analysis of Covid-19 mRNA vaccine trial data and post-injection injury. The authors of the article also called for a global moratorium on vaccines.
Dr. Peter McCullough, one of the authors of the article, called the retraction “a stunning act of scientific censorship.” He told the Defender:
“The journal and its editors had the right to reject the article at any time during the review process. Once published, retraction of an article without adequate justification constitutes a violation of the Committee on Publication Ethics (COPE) guidelines.”
The document, published last month, describes in detail the serious potential harms of vaccines, problems in vaccine control and treatment, the mechanisms behind adverse reactions, the immunological reasons for vaccine ineffectiveness and the mortality data from registration trials.
The authors of the article concluded:
“The federal agency's approval of Covid-19 mRNA injectable products based on general population coverage was not supported by an honest assessment of all relevant registration data and by a proportional consideration of risks compared to benefits.
They also demanded that the vaccines be immediately removed from the CDC (Centers for Disease Control and Prevention) childhood immunization schedule and that booster shots be suspended.
The document was read more than 350 times in the month following its publication. The average Cureus article is only viewed about 000 times in an entire year.
McCullough said Tim Kersjes, head of research integrity at Springer Nature, which publishes Cureus, informed the authors last week that the journal was retracting the paper. Mr Kersjes raised eight points of concern, which Mr McCullough said the authors had already addressed through an exhaustive peer review process.
Dr McCullough told the Defender:
“I suspect Kersjes and Springer Nature were pressured by the powerful bio-pharmaceutical complex, made up of coordinated public health organizations, vaccine manufacturers and regulators, to censor our article in order to prevent the medical community from obtaining crucial information about vaccine safety.
“We have rejected the retraction, we have appealed, and we will report this unethical action to all relevant authorities, while continuing to publish elsewhere.”
Mr Nathaniel Mead, the lead author of the article, told the Defender that he had feared from day one that the journal would come under pressure to retract the article.
I knew as soon as I hit the “publish” button on Cureus on January 24, following an extensive review process and multiple resubmissions, that we were dealing with a ticking time bomb.” , Mr. Mead said.
“By citing strong evidence and exposing how industry-sponsored trials misled the public, our evidence-based article was a true indictment of the COVID-19 vaccine company.”
“Predatory Retractions” Benefit Big Pharma
John Adler of Stanford University and Alexander Muacevic of the University of Munich founded Cureus in 2009. It is an open-access, peer-reviewed online general medical journal with Publication costs are low.
Academic publishing giant Springer Nature acquired Cureus in December 2022.
Springer Nature is a publishing conglomerate founded in 2015 through the merger of Nature Publishing Group, Palgrave Macmillian, Macmillan Education and Springer Science+Business Media.
The publisher generated €1,8 billion in 2022, showing continued year-on-year growth since 2020.
Springer Nature has an internal research integrity group responsible for ensuring that the company's scientific content is “rigorously evaluated”. When questions arise that require the intervention of “research integrity experts,” the resolution team, led by Mr. Kersjes, steps in.
On February 16, Mr. Kersjes informed the authors that the journal's editors planned to retract the article, saying that the journal “had recently been informed of several concerns regarding the validity of the work.”
According to the text of the email, posted on Substack by Steve Kirsch, another of the paper's co-authors, these concerns “cannot, in our opinion, be resolved by a correction.”
Mr. Kersjes told the authors that they had the option to accept or decline the retraction, which would be indicated on the website.
They did not agree. “We vigorously reject this arbitrary and capricious decision, taken after the fact, on the part of Mr. Kersjes and his superiors at Springer,” they wrote.
Mr. Kersjes' letter raises concerns about the authors' claims about all-cause mortality data, the Vaccine Adverse Event Reporting System (VAERS), the number of deaths due to vaccination compared to number of lives saved, the possibility of vaccine contamination, the claim that vaccines have not been adequately tested for safety and effectiveness, the “incorrect” statement that spike proteins remain in the body and can have harmful effects and that vaccines are gene therapy products.
In their rebuttal, the authors responded to each criticism by explaining their argument and providing supporting quotes. They noted that the paper's eight reviewers and the journal's editors found their responses satisfactory.
A few days after the initial publication, Mr. Adler, who is the editor-in-chief of Cureus, told the industry-friendly website Retraction Watch: “Our editorial response has been increased vigilance during the publication process. peer review, with 8 different reviewers weighing in on whether to publish, including a few with strong statistical backgrounds. Therefore, a credible peer review process was followed and the consequences fell as they should.
Mr Adler also said the journal would re-evaluate if “fatal flaws” were identified. “Cureus' decision-making process contrasts sharply with Elsevier's editorial decision to censor the article using ad hominem arguments.
However, a Cereus spokesperson told the Defender today: “Following publication, concerns were raised regarding a number of claims made in the article and an investigation by Cureus and the Springer team Nature's Research Integrity Charge identified several issues with the article that warranted a retraction”.
The spokesperson added: “It is preferable for such issues to be detected during peer review, but this is unfortunately not always the case. It is therefore important, as happened in this case, that when issues are raised after publication, they are addressed promptly in order to preserve the integrity of the academic record.”
The authors say in their rebuttal that most of the concerns “appear to be adapted, directly or indirectly, from the many comments made by well-known vaccine industry trolls on social media, Jonathan Laxton and Matthew Dopler,” who have frequently commented on the article on the Cureus website.
[...]
Last modification 54 there is
The Devil's Comet could become visible to the naked eye as early as March 2024
The Devil's Comet could become visible to the naked eye as early as March 2024Jacob's Ladder - Feb 29, 2024
A comet observed for centuries seems promising. Nicknamed “devil’s comet”, 12P/Pons-Brooks seems on track to become visible to the naked eye in 2024.
Will the next comet visible to the naked eye in France be the “devil’s comet”? It's still a little early to say. There is, however, hope with this specimen, whose brightness could make it visible without an instrument in the sky of March or April 2024.
The measurement of magnitude is used to describe the apparent brightness of a star. The brighter the object, the lower its magnitude. The naked eye's limiting magnitude is 6; that of the full Moon, -12,6.
From its official name 12P/Pons-Brooks, this comet could reach an apparent magnitude of 7,1 up to 5,2 throughout the month of March, indicated BBC Sky at Night on February 19. If the comet's magnitude changes as this prediction indicates, it would mean that its brightness would be very close to what the naked eye can perceive. The comet's perihelion, that is to say the moment when it will be closest to the Sun on its trajectory, is scheduled for April 21.
Already, astrophotographers have begun to hunt this beautiful comet and publish their images of its greenish hair and its bluish tail.
The Devil's Comet, observed for centuries by astronomers
Why is it nicknamed “devil’s comet”? In July, 12P/Pons-Brooks expelled a lot of gas and dust, suddenly becoming brighter. This explosion distorted the comet's hair, with a dark center and two brighter tips, giving the impression that it had horns (like those of a devil). Then, scientists found that this behavior was not so rare for 12P/Pons-Brooks, who has already experienced this kind of episodes.
Comet 12P/Pons-Brooks is well known to astronomers: its first observations date back to the 14th century. The history of this comet is rich. In 1812, the French astronomer Jean-Louis Pons discovered the comet using his telescope in Marseille. Then, in 1883, the American astronomer William Robert Brooks in turn rediscovered the comet. The celestial object therefore took the name of its two discoverers. Further observations by scientists made it possible to make the link between the recent appearances of 12P/Pons-Brooks and observations made in 1385 and 1457, corresponding well to this object.
It is a Halley-type comet, in reference to the most famous of all comets. This category includes comets whose orbital period is between 20 and 200 years. For 12P/Pons-Brooks, this period is approximately 71 years. The comet has therefore already had multiple opportunities to venture into the inner solar system.
It is always very difficult to predict with certainty whether a comet will become clearly visible to the naked eye. They are very unpredictable celestial objects, which can behave in surprising ways as they approach the Sun. After its passage in the terrestrial neighborhood in 2021, comet Leonard disintegrated – a few lucky people were able to see it with their own eyes before this disastrous outcome.
Last modification 54 there is
Gemini, Google's ultra-Woke engine
Jacob's Ladder - Feb 27, 2024
Last week, while OpenAI was thrilling the world of artificial intelligence with Sora, the first engine allowing the creation of small, realistic videos from a simple textual description, Alphabet (the parent company of Google) launched boasts the new version of its conversational agent, the global company's response to ChatGPT from OpenAI, itself owned by Microsoft. The least we can say is that we were not disappointed.
As usual to properly launch its product, Google subtly changed the name from Bard to Gemini (as it had gone from Google Apps to GSuite then Workspace, or from Google Local to Places to MyBusiness to Business Profile, or Google Hangouts to Chat, etc.) while giving it new features.
It must be recognized that Google's artificial intelligence engine is powerful.
The next few weeks will undoubtedly allow us to explore in detail what it has under the hood, but we already know, for example, that Gemini now has a pop-up of one million tokens. This pop-up window is what allows the agent to remember the exchanges from one question to the next. By comparison, ChatGPT 3.5 (the free version) has a window of around 16.000 tokens and version 4 allows up to 128.000 tokens and to give an order of magnitude, this last number represents the equivalent of a book of pocket roughly, where Gemini can remember a complete work of 1.500 pages…
Or a film of around an hour and a half: Gemini allows the user to provide images or videos as contextual input on which to base their responses; to quickly summarize a video, this may prove particularly interesting in the near future.
But alongside these undeniable technical advances and truly interesting power, Gemini stood out above all for the very rapid identification of a problem that was quite embarrassing for the Mountain View firm in California: undoubtedly wanting to catch up in in terms of image production from a textual description – OpenAI has indeed been allowing its clients to produce images for several months directly from ChatGPT – Gemini was equipped with this possibility but in use, it quickly became apparent that certain requests were simply not accepted or the gap between requests and results was so great that, very quickly, social networks took over the matter.
No doubt: when Gemini is asked to produce images with historical content or representing certain ethnic groups, the latter interprets the request a little too specifically.
Thus, obtaining the image of a medieval knight or a pope results in the production of images systematically in gross disagreement with reality: Google's artificial intelligence enjoys creating, with suspicious enthusiasm, knights medievals of all possible ethnicities but the blond knight with blue eyes is strangely absent; the images of popes produced happily draw on women, possibly Indian or black; as for the Roman emperors, they are all surprisingly very African.
The milestone was reached when faced with the request to represent German soldiers in 1943, Gemini saw fit to produce a series of resolutely inclusive images including proud black representatives of the Wehrmacht... Who still doubted that historical reality could bend as easily to the most modern constraints?
Last modification 54 there is
The Sun is unleashed: several eruptions are heading towards the Earth
The Sun is unleashed: several eruptions are heading towards the EarthSott: Sign of The Times - Feb 18, 2024
Our Sun sometimes, when it erupts, expels kinds of plasma clouds. Astronomers call them coronal mass ejections (CMEs).
In recent days, the Sun, which is ever approaching the peak of its activity, has sent towards Earth, not one, but several of these CMEs. Models estimate that at least three of them should hit our Earth on February 13, 2024.
Enough to trigger minor to moderate geomagnetic storms, class G1 to G2. With northern lights which should not become visible at very low latitudes.
Our Sun sometimes, when it erupts, expels kinds of plasma clouds. Astronomers call them coronal mass ejections (CMEs). In recent days, the Sun, which is ever approaching the peak of its activity, has sent towards Earth, not one, but several of these CMEs. Models estimate that at least three of them should hit our Earth on February 13, 2024.
A possibility of a strong solar storm caused by a coronal mass ejection
Enough to trigger minor to moderate geomagnetic storms, class G1 to G2. With northern lights which should not become visible at very low latitudes.
But the possibility remains for a rarer event to occur. Researchers speak of cannibalistic CME. Because not all coronal mass ejections move through space at the same speed. If one of those on its way to Earth were to be faster than the others, it could catch up with them. The combined power of these CMEs would then give rise to a strong solar storm, class G3. And potentially, the northern lights up to mid-latitudes.
Last modification 54 there is
Musk's company Neuralink implanted the first implant in the human brain
Musk's company Neuralink implanted the first implant in the human brainInternational Network - Feb 01, 2024
American entrepreneur Elon Musk's neurotechnology company, Neuralink, has implanted an implant in the human brain for the first time.
“The first human received a Neuralink implant yesterday and is recovering well,” Elon Musk posted on X.
“The first results show promising detection of neuronal spikes,” he adds.
“Our mission: Create a generalized brain interface to restore autonomy to those whose medical needs are not met today and unleash the human potential of tomorrow,” announces the Neuralink website.
“Our brain-computer interface is fully implantable, aesthetically invisible and designed to allow you to control a computer or mobile device wherever you go,” it says.
The entrepreneur added that Neuralink's first product is called Telepathy. This will allow a person to control their phone and computer through the power of thought. “The first users will be people who have lost control of their limbs,” Elon Musk said.
Neuralink is recruiting candidates: “If you would like to know if you might be eligible for current and/or future Neuralink clinical trials, consider joining our patient registry.”
Last modification 54 there is
Water and consciousness
Water and consciousnessVodaflor - January 29, 2024
Conference by Dr Guy Londechamp - made available by Dr Olivier Soulier - www.lessymboles.com
“CARE MAN, SAVE THE EARTH”.
Understand “memory and the genius of water” and its essential role on both consciousness and social life.
Last modification 54 there is
Live with Next Dose, Ricardo Delgado, Astrid Stuckelberger and Dominique Guillet
Live with Next Dose, Ricardo Delgado, Astrid Stuckelberger and Dominique GuilletRevolution 2030: other source - January 05, 2024
The world & us: A show by Jacky Cassou.
To find each of the guests on their broadcast channels:
- Next Dose has a website (https://www.nextdose.fr/) and a Telegram page (t.me/next_dose_officiel)
- La Quinta Columna regularly posts videos translated into French and other languages on Odysee (https://odysee.com/@laquintacolumnainternational:7?view=content) and Telegram (t.me/laquintacolumnainternational)
- Dr Astrid Stuckelberger, who we recall had direct experience of the functioning of the highest health authority in the world as an expert and investigator with the WHO but also with the EU before becoming a internationally renowned whistleblower. On Telegram (t.me/Dr_Astrid_Stuckelberger) and X (https://twitter.com/Stuckelberger)
- Dominique Guillet is on VK (https://vk.com/xochipelli no connection required), on Telegram (t.me/brigadesantigraphene) and on X (https://twitter.com › Xochipelli1953). Its website (https://xochipelli.fr/) is currently being reorganized as it is full but will very quickly be accessible again.
Last modification 54 there is
Starlink global traffic triples in 2023
Digital Dawn - 24 Dec 2023
Crowning Elon Musk as the leader of the spatial internet.
New data from IT security firm Cloudflare reveals a surge in popularity for Elon Musk's Starlink internet service, with global web traffic tripling this year.
“Overall, we have seen Starlink traffic more than triple this year. In the United States, Starlink traffic increased more than 2,5 times, and increased 17 times in Brazil. In countries where Starlink will go live in 2023, including Kenya, the Philippines, and Zambia, we saw traffic increase rapidly as soon as the service became available,” Cloudflare writes in its report.
Starlink's satellite broadband internet service has grown exponentially over the past three years. This development is due to the increase in launches by SpaceX of Starlink satellites into low Earth orbit.
Starlink is the world's leading internet service provider in space. Jeff Bezos' Project Kuiper service is very late, with only a few satellites in low orbit. Bezos recently had to hire Musk for rocket launches after his rocket company Blue Origin suffered a series of delays over the summer.
Starlink had more than two million users as of September and operated on all seven continents in more than 60 countries.
Last modification 54 there is
Genetically modified humans?
The Defender – Dec 01, 2023
Scientists sound alarm as UK approves CRISPR therapy to treat blood disease.
British regulators this week approved the first CRISPR therapy for treating humans and US regulators could approve the therapy - designed to treat blood disorders - as early as December. At the same time, the US company behind another CRISPR technology, "base editing", reported a successful initial study, although two of the ten subjects suffered heart attacks, leading to the death of a trial participant.
British regulators on Thursday approved a therapy using CRISPR gene-editing technology to treat two blood diseases. U.S. federal regulators are poised to approve this same treatment in December.
The exa-cel therapy, which goes by the brand name Casgevy, is the first CRISPR therapy for humans to be approved for the market.
CRISPR is a gene-editing technology that acts like a pair of “genetic scissors,” allowing scientists to modify sections of DNA by “cutting out” specific portions and replacing them with new segments. First announced in a 2012 paper, CRISPR is considered a simple and inexpensive way to edit genes.
Its inventors were awarded the Nobel Prize in Chemistry in 2020. In recent years, applications in plant manipulation and research into possible use in humans have proliferated, with the technology being touted as a potential solution to issues ranging from disease to food security to climate change.
But this research has been highly controversial, and a long series of papers have been published detailing the unintended effects of CRISPR gene editing, which has been shown to produce many types of severe, unintended DNA damage.
Casgevy is designed to treat two blood diseases: sickle cell disease and beta thalassemia. Sickle cell disease, also known as sickle cell anemia, occurs most often in people of African or Caribbean descent. It can cause debilitating pain.
People with beta thalassemia, which can cause mild or severe anemia, may need regular blood transfusions.
Both of these genetic diseases are caused by errors in the genes for hemoglobin, a protein that allows red blood cells to carry oxygen around the body, and both can be fatal.
The therapy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, was approved after a sickle cell trial that followed only 29 participants out of a total of 45 for 16 months. Twenty-eight of the people monitored no longer had pain after a year, according to Nature.
In the clinical trial for beta thalassemia, 39 of 42 trial participants did not need to receive a red blood cell transfusion for at least 12 months after receiving Casgevy. They usually need blood transfusions every three to five weeks.
